Table 1 Correlation between CBX7 expression in gastric cancer tissues and clinicopathological variables
CBX7(+) | CBX7(−) | P value | |
|---|---|---|---|
Lymph node metastases | |||
Negative | 5 (23.8%) | 16 (76.2%) | 0.054 |
Positive | 35 (47.3%) | 39 (52.7%) | |
Depth of invasion | |||
T1–3 | 16 (42.1%) | 22 (57.9%) | 1.000 |
T4 | 24 (42.1%) | 33 (57.9%) | |
TNM staging | |||
Stage I | 0 (0%) | 4 (100%) | 0.072 |
Stage II | 7 (31.8%) | 15 (68.2%) | |
Stage III | 26 (47.3%) | 29 (52.7%) | |
Stage IV | 7 (50.0%) | 7 (50.0%) | |
Degree of differentiation | |||
Moderately/moderately-poorly differentiated | 16 (38.1%) | 26 (61.9%) | 0.481 |
Poorly differentiated | 24 (45.3%) | 29 (54.7%) | |
Pathological types | |||
Adenocarcinoma | 27 (40.3%) | 40 (59.7%) | 0.581 |
Signet-ring cell carcinoma/myxoadenocarcinoma | 13 (46.4%) | 15 (53.6%) | |
Lymphatic or vascular invasion | |||
Positive | 28 (46.7%) | 32 (53.3%) | 0.238 |
Negative | 12 (34.3%) | 23 (65.7%) | |
Nerve invasion | |||
Positive | 26 (45.6%) | 31 (54.4%) | 0.396 |
Negative | 14 (36.8%) | 24 (63.2%) | |
Age(years) | |||
≥ 60 | 16 (42.1%) | 22 (57.9%) | 1.000 |
< 60 | 24 (42.1%) | 33 (57.9%) | |
Gender | |||
Male | 24 (35.8%) | 43 (64.2%) | 0.055 |
Female | 16 (57.1%) | 12 (42.9%) | |